Genetic Heterogeneity Underlying Phenotypes with Early-Onset Cerebellar Atrophy.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
16 Nov 2023
Historique:
received: 14 09 2023
revised: 01 11 2023
accepted: 09 11 2023
medline: 27 11 2023
pubmed: 25 11 2023
entrez: 25 11 2023
Statut: epublish

Résumé

Cerebellar atrophy (CA) is a frequent neuroimaging finding in paediatric neurology, usually associated with cerebellar ataxia. The list of genes involved in hereditary forms of CA is continuously growing and reveals its genetic complexity. We investigated ten cases with early-onset cerebellar involvement with and without ataxia by exome sequencing or by a targeted panel with 363 genes involved in ataxia or spastic paraplegia. Novel variants were investigated by

Identifiants

pubmed: 38003592
pii: ijms242216400
doi: 10.3390/ijms242216400
pmc: PMC10671053
pii:
doi:

Substances chimiques

TBCD protein, human 0
Microtubule-Associated Proteins 0
CLN6 protein, human 0
Membrane Proteins 0
SETX protein, human EC 3.6.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI18/00147
Organisme : Instituto de Salud Carlos III
ID : PI21/00103
Organisme : Instituto de Salud Carlos III
ID : FI19/00072

Références

Front Neurol. 2021 Mar 02;12:639994
pubmed: 33737904
Nat Genet. 2004 Mar;36(3):225-7
pubmed: 14770181
Mov Disord. 2022 May;37(5):905-935
pubmed: 35481685
Nature. 2019 Dec;576(7787):492-497
pubmed: 31766050
Pediatr Neurol. 2023 Feb;139:59-64
pubmed: 36527993
Am J Hum Genet. 2009 Aug;85(2):281-9
pubmed: 19646678
Hum Mol Genet. 2006 May 15;15(10):1587-99
pubmed: 16595610
PLoS One. 2010 Jan 22;5(1):e8846
pubmed: 20107510
Mol Psychiatry. 2015 Feb;20(2):176-82
pubmed: 25666757
Eur J Neurol. 2014 Apr;21(4):607-15
pubmed: 24765663
Brain. 2017 Jun 1;140(6):1579-1594
pubmed: 28444220
Neurogenetics. 2005 Sep;6(3):107-26
pubmed: 15965709
Parkinsonism Relat Disord. 2019 Apr;61:179-186
pubmed: 30340910
Hum Mol Genet. 2001 Apr 1;10(8):797-806
pubmed: 11285245
Hum Mol Genet. 2022 Nov 10;31(22):3897-3913
pubmed: 35766882
J Biol Chem. 1998 Dec 18;273(51):34341-8
pubmed: 9852100
EMBO J. 2017 Jun 1;36(11):1590-1604
pubmed: 28408439
Brain. 2009 Oct;132(Pt 10):2688-98
pubmed: 19696032
Hum Mol Genet. 2019 May 15;28(10):1629-1644
pubmed: 30624633
Clin Genet. 2018 Apr;93(4):731-740
pubmed: 28542792
Neurosci Lett. 2019 Jan 1;688:62-75
pubmed: 29997061
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W382-8
pubmed: 15980494
Cell Metab. 2010 Jan;11(1):23-34
pubmed: 20074525
J Mol Neurosci. 2020 Mar;70(3):320-327
pubmed: 31721002
J Child Neurol. 2012 Sep;27(9):1121-32
pubmed: 22764178
Int J Mol Sci. 2021 Mar 02;22(5):
pubmed: 33801522
Am J Hum Genet. 2004 Jun;74(6):1128-35
pubmed: 15106121
Neuron. 2018 Dec 19;100(6):1354-1368.e5
pubmed: 30449657
Mov Disord. 2020 Dec;35(12):2139-2149
pubmed: 33044027
Am J Hum Genet. 2002 Feb;70(2):324-35
pubmed: 11791207
Hum Mol Genet. 2017 Oct 1;26(19):3749-3762
pubmed: 28934387
Brain. 2018 Jul 1;141(7):1998-2013
pubmed: 29878067
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
Brain. 2007 Oct;130(Pt 10):2646-60
pubmed: 17872929
Nucleic Acids Res. 2022 Jan 7;50(D1):D439-D444
pubmed: 34791371
Am J Hum Genet. 2016 Oct 6;99(4):962-973
pubmed: 27666370
BMC Bioinformatics. 2010 Nov 08;11:548
pubmed: 21059217
Am J Hum Genet. 2016 Oct 6;99(4):950-961
pubmed: 27666374
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Eur J Med Genet. 2023 Nov;66(11):104853
pubmed: 37758169
Nature. 2016 Sep 8;537(7619):191-196
pubmed: 27580036
Hum Mutat. 2018 Mar;39(3):415-432
pubmed: 29235198
Neurogenetics. 2017 Dec;18(4):245-250
pubmed: 28975462
Orphanet J Rare Dis. 2022 May 3;17(1):179
pubmed: 35505348
Mol Cell. 2013 Aug 22;51(4):423-39
pubmed: 23973373
Neuropediatrics. 2015 Dec;46(6):359-70
pubmed: 26444039
Int J Mol Sci. 2022 Oct 06;23(19):
pubmed: 36233161
Eur J Hum Genet. 2018 Oct;26(10):1512-1520
pubmed: 29921875
Mov Disord Clin Pract. 2020 Sep 29;7(8):940-949
pubmed: 33163565
Neuron. 2019 Feb 20;101(4):560-583
pubmed: 30790538
Biochem Pharmacol. 2023 Sep;215:115717
pubmed: 37516277
Ann Neurol. 2019 Jul;86(1):99-115
pubmed: 31004438
Cell. 2012 Aug 3;150(3):533-48
pubmed: 22863007
J Biol Chem. 1991 Feb 25;266(6):3402-7
pubmed: 1704889
Proteomics. 2021 Oct;21(19):e2100043
pubmed: 34432360
Lancet Neurol. 2023 Aug;22(8):735-749
pubmed: 37479376
Am J Hum Genet. 2015 Nov 5;97(5):726-37
pubmed: 26456284
Cells. 2021 Dec 30;11(1):
pubmed: 35011673
Eur J Paediatr Neurol. 2008 May;12(3):155-67
pubmed: 17869142
Neuropediatrics. 2020 Dec;51(6):435-439
pubmed: 32818970
Clin Genet. 2014 Oct;86(4):335-41
pubmed: 24102492
Am J Med Genet C Semin Med Genet. 2022 Mar;190(1):72-88
pubmed: 35238134
Brain. 2021 Dec 31;144(12):3597-3610
pubmed: 34415310
Am J Med Genet A. 2020 Jun;182(6):1483-1490
pubmed: 32198973
Mov Disord. 2018 Jul;33(7):1056-1076
pubmed: 29756227
Clin Genet. 2020 May;97(5):758-763
pubmed: 32043565
Brain. 2021 Oct 22;144(9):2659-2669
pubmed: 34415322

Auteurs

Dolores Martínez-Rubio (D)

Rare Neurodegenerative Diseases Laboratory, Valencia Biomedical Research Foundation, Centro de Investigación Príncipe Felipe (CIPF), 46012 València, Spain.
Joint Unit CIPF-IIS La Fe Rare Diseases, 46012 València, Spain.

Isabel Hinarejos (I)

Rare Neurodegenerative Diseases Laboratory, Valencia Biomedical Research Foundation, Centro de Investigación Príncipe Felipe (CIPF), 46012 València, Spain.
Joint Unit CIPF-IIS La Fe Rare Diseases, 46012 València, Spain.

Herminia Argente-Escrig (H)

Department of Neurology, Hospital Universitari Arnau de Vilanova, 46012 València, Spain.

Clara Marco-Marín (C)

Structural Enzymopathology Unit, Instituto de Biomedicina de Valencia (IBV), Consejo Superior de Investigaciones Científicas (CSIC), 46022 València, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.

María Ana Lozano (MA)

Rare Neurodegenerative Diseases Laboratory, Valencia Biomedical Research Foundation, Centro de Investigación Príncipe Felipe (CIPF), 46012 València, Spain.

Nerea Gorría-Redondo (N)

Paediatric Neurology Unit, Department of Paediatrics, Hospital Universitario de Navarra, Navarrabiomed, 31008 Pamplona, Spain.

Vincenzo Lupo (V)

Rare Neurodegenerative Diseases Laboratory, Valencia Biomedical Research Foundation, Centro de Investigación Príncipe Felipe (CIPF), 46012 València, Spain.

Itxaso Martí-Carrera (I)

Paediatric Neurology Unit, Department of Paediatrics, Hospital Universitario Donostia, 20014 Donostia, Spain.

Concepción Miranda (C)

Paediatric Neurology Unit, Department of Paediatrics, Hospital General Universitario Gregorio Marañón, 28027 Madrid, Spain.

María Vázquez-López (M)

Paediatric Neurology Unit, Department of Paediatrics, Hospital General Universitario Gregorio Marañón, 28027 Madrid, Spain.

Asunción García-Pérez (A)

Paediatric Neurology Unit, Department of Paediatrics, Hospital Universitario Fundación Alcorcón, Alcorcón, 28922 Madrid, Spain.

Ana Victoria Marco-Hernández (AV)

Paediatric Neurology Unit, Department of Paediatrics, Hospital Universitari Doctor, Peset, 46017 València, Spain.

Miguel Tomás-Vila (M)

Paediatric Neurology Unit, Department of Paediatrics, Hospital Universitari i Politècnic La Fe, 46026 València, Spain.

Sergio Aguilera-Albesa (S)

Paediatric Neurology Unit, Department of Paediatrics, Hospital Universitario de Navarra, Navarrabiomed, 31008 Pamplona, Spain.

Carmen Espinós (C)

Rare Neurodegenerative Diseases Laboratory, Valencia Biomedical Research Foundation, Centro de Investigación Príncipe Felipe (CIPF), 46012 València, Spain.
Joint Unit CIPF-IIS La Fe Rare Diseases, 46012 València, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain.
Biotechnology Department, Universitat Politècnica de València, 46022 València, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH